Metabolism and Disposition of the Antihypertensive Agent Moxonidine in Humans
| Autor: | Hans C. Schaefer, Stuart D. Oliver, Isabelle J. Pouliquen, Christopher D. Payne, Malcolm I. Mitchell, Thomas J. Lindsay, Trent L. Abraham, Minxia M. He, Lisa A. Shipley, Boris A. Czeskis |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Male
medicine.medical_specialty Metabolite Administration Oral Pharmaceutical Science Urine Pharmacology Mass Spectrometry Excretion chemistry.chemical_compound Pharmacokinetics Oral administration Internal medicine medicine Humans Antihypertensive Agents Aged Moxonidine Imidazoles Area under the curve Metabolism Middle Aged Endocrinology chemistry Area Under Curve medicine.drug |
| Zdroj: | Drug Metabolism and Disposition. 31:334-342 |
| ISSN: | 1521-009X 0090-9556 |
| Popis: | The metabolism and pharmacokinetics of moxonidine, a potent central-acting antihypertensive agent, were studied in four healthy subjects after a single oral administration of approximately 1 mg (approximately 60 muCi) of [(14)C(3)]moxonidine. Moxonidine was rapidly absorbed, with peak plasma concentration achieved between 0.5 to 2 h postdose. The maximal plasma concentration and the area under the curve of unchanged moxonidine are lower than those determined for radioactivity, indicating presence of circulating metabolite(s). The total recovery of radiocarbon over 120 h ranged from 99.6 to 105.2%, with 92.3 to 103.3% of the radioactivity excreted in the urine and only 1.9 to 7.3% of the dose excreted in the feces. Thus, renal elimination represented the principal route of excretion of radioactivity. Metabolites of moxonidine were identified in urine and plasma samples by high performance liquid chromatography and liquid chromatography-tandem mass spectrometry. Oxidation of moxonidine on the methyl group or on the imidazoline ring resulted in the formation of hydroxymethyl moxonidine, hydroxy moxonidine, dihydroxy moxonidine, and dehydrogenated moxonidine. Metabolite profiling results indicated that parent moxonidine was the most abundant component in the urine. The dehydrogenated moxonidine was the major urinary metabolite as well as the major circulating metabolite. Moxonidine also underwent phase II metabolism, generating a cysteine conjugate. In summary, moxonidine is well absorbed after oral administration. The major clearance pathway for moxonidine in humans is via renal elimination. Furthermore, seven metabolites were identified with three metabolites unique to humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|